Our results suggest that injection into CSF of antibodies targeting TDP-43 should be considered as a new potential therapeutic approach for the treatment of sporadic forms of ALS and of other neurodegenerative disorders with TDP-43 proteinopathy. Here, TARDBP is linked to amyotrophic lateral sclerosis.